Advancements in the design and development of pyrazoline-based antimycobacterial agents: an update and future perspectives

target interaction and ADMET studies are also covered. A dedicated section is included to showcase target-oriented strategies (InhA, cytochrome P450 14α-sterol demethylase, and enzymes involved in the mycobactin biosynthesis pathway), recent patents, suggested schemes for reported pyrazolines, and an overview of research methodologies and evaluation models. We believe that this review will enable medicinal chemists to map unexplored chemical space in identifying critical research gaps. This is essential for the rational design and development of potent antitubercular agents against tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and other non-tubercular mycobacterial diseases (NTMD).